Since COVID-19 started making headlines – and capturing the collective attention of the world in early 2020, several pharmaceutical companies began working around the clock to develop a vaccine, as scores of others worked overtime to ensure the availability of therapeutics to address the virus’s short- and long-term symptoms.
However, there are only so many hours in any full-time employee’s day – and working around the clock can only be sustained for so long. So, for many biopharma companies, the reality is that time spent on the most mission-critical COVID-19-related projects has often meant that other regulatory approval and compliance initiatives are ending up reprioritized or delayed.
Savvy drug developers are leveraging dedicated, full-time equivalent (FTE) staffing models to bridge the gap.
For years, FTE staffing models have been used as a more cost-effective, scalable and flexible solution for companies that want to avoid the inefficiencies and overhead costs of hiring full-time staff to manage regulatory filings, compliance, post-approval and other initiatives. Since the beginning of the pandemic in particular, many of the manufacturers that utilize Cardinal Health Regulatory Sciences’ FTE model offering have leveraged this service as a cost-efficient way to ensure they’re able to aggressively pursue COVID-19-related projects; while not neglecting other regulatory priorities.